CEL-SCI Corporation, a clinical stage cancer immunotherapy company, has announced the closing of a $5.7 million offering under NYSE American rules. The company sold 1,500,000 shares of its common stock at $3.82 per share. The proceeds from the offering are intended to support the continued development of CEL-SCI's Multikine product, as well as for general corporate purposes and working capital. ThinkEquity acted as the sole placement agent for this offering. The securities were offered under a shelf registration statement filed with the U.S. Securities and Exchange Commission.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。